This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyskens, F. L. Articles by Gerner, E. W. Search for Related Content PubMed PubMed Citation Articles by Meyskens, F. L., Jr. Articles by Gerner, E. W.

Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent¹

Departments of Medicine (Hematology/Oncology) and Biological Chemistry and the Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92668 [F. L. M.], and Departments of Radiation Oncology and Biochemistry, Arizona Cancer Center, Tucson, Arizona 85724 [E. W. G.]

D,L--difluoromethylornithine (DFMO) was synthesized over 20 years ago. It was hoped that this enzyme-activated, irreversible inhibitor of ornithine decarboxylase, the first enzyme in polyamine synthesis, would be effective as a chemotherapy for hyperproliferative diseases, including cancer and/or infectious processes. DFMO was generally found to exert cytostatic effects on mammalian cells and tissues, and its effectiveness as a therapeutic agent has been modest. DFMO was also found to cause treatment-limiting (but reversible) ototoxicity at high doses. This side effect, along with its minimal therapeutic activity, contributed to the loss of interest by many clinicians in further developing DFMO as a cancer therapeutic agent. However, DFMO was subsequently shown to inhibit carcinogen-induced cancer development in a number of rodent models, and interest in developing this compound as a preventive agent has increased. The rationale for the inhibition of ornithine decarboxylase as a cancer chemopreventive agent has been strengthened in recent years because this enzyme has been shown to be transactivated by the c-myc oncogene in certain cell/tissue types and to cooperate with the ras oncogene in malignant transformation of epithelial tissues. Recent clinical cancer chemoprevention trials, using dose de-escalation designs, indicate that DFMO can be given over long periods of time at low doses that suppress polyamine contents in gastrointestinal and other epithelial tissues but cause no detectable hearing loss or other side effects. Current clinical chemoprevention trials are investigating the efficacy of DFMO to suppress surrogate end point biomarkers (e.g., colon polyp recurrence) of carcinogenesis in patient populations at elevated risk for the development of specific epithelial cancers, including colon, esophageal, breast, cutaneous, and prostate malignancies.

This article has been cited by other articles:

				X. Wang, S. Levic, M. A. Gratton, K. J. Doyle, E. N. Yamoah, and A. E. Pegg Spermine Synthase Deficiency Leads to Deafness and a Profound Sensitivity to {alpha}-Difluoromethylornithine J. Biol. Chem., January 9, 2009; 284(2): 930 - 937. [Abstract] [Full Text] [PDF]

				M. D. Hogarty, M. D. Norris, K. Davis, X. Liu, N. F. Evageliou, C. S. Hayes, B. Pawel, R. Guo, H. Zhao, E. Sekyere, et al. ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma Cancer Res., December 1, 2008; 68(23): 9735 - 9745. [Abstract] [Full Text] [PDF]

				G. E. Goodman Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin Cancer Prevention Research, December 1, 2008; 1(7): 499 - 502. [Full Text] [PDF]

				C. E. McLaren, S. Fujikawa-Brooks, W.-P. Chen, D. L. Gillen, D. Pelot, E. W. Gerner, and F. L. Meyskens Jr. Longitudinal Assessment of Air Conduction Audiograms in a Phase III Clinical Trial of Difluoromethylornithine and Sulindac for Prevention of Sporadic Colorectal Adenomas Cancer Prevention Research, December 1, 2008; 1(7): 514 - 521. [Abstract] [Full Text] [PDF]

				F. L. Meyskens Jr., C. E. McLaren, D. Pelot, S. Fujikawa-Brooks, P. M. Carpenter, E. Hawk, G. Kelloff, M. J. Lawson, J. Kidao, J. McCracken, et al. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial Cancer Prevention Research, June 1, 2008; 1(1): 32 - 38. [Abstract] [Full Text] [PDF]

				R. A. Hubner, K. R. Muir, J.-F. Liu, R. F.A. Logan, M. J. Grainge, R. S. Houlston, and Members of the UKCAP Consortium Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention Clin. Cancer Res., April 15, 2008; 14(8): 2303 - 2309. [Abstract] [Full Text] [PDF]

				D. Z. J. Chu, G. Gibson, D. David, and Y. Yen The Surgeon's Role in Cancer Prevention. The Model in Colorectal Carcinoma Ann. Surg. Oncol., November 1, 2007; 14(11): 3054 - 3069. [Abstract] [Full Text] [PDF]

				I. Basu, G. Cordovano, I. Das, T. J. Belbin, C. Guha, and V. L. Schramm A Transition State Analogue of 5'-Methylthioadenosine Phosphorylase Induces Apoptosis in Head and Neck Cancers J. Biol. Chem., July 20, 2007; 282(29): 21477 - 21486. [Abstract] [Full Text] [PDF]

				L. M. Petros, G. F. Graminski, S. Robinson, M. R. Burns, N. Kisiel, R. F. Gesteland, J. F. Atkins, D. L. Kramer, M. T. Howard, and R. S. Weeks Polyamine Analogs with Xylene Rings Induce Antizyme Frameshifting, Reduce ODC Activity, and Deplete Cellular Polyamines J. Biochem., November 1, 2006; 140(5): 657 - 666. [Abstract] [Full Text] [PDF]

				U. K. Basuroy and E. W. Gerner Emerging Concepts in Targeting the Polyamine Metabolic Pathway in Epithelial Cancer Chemoprevention and Chemotherapy J. Biochem., January 1, 2006; 139(1): 27 - 33. [Abstract] [Full Text] [PDF]

				R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]

				R. L. e Silva, Y. Saishin, Y. Saishin, H. Akiyama, S. Kachi, S. Aslam, B. Rogers, T. Deering, Y. Y. Gong, S. F. Hackett, et al. Suppression and Regression of Choroidal Neovascularization by Polyamine Analogues Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3323 - 3330. [Abstract] [Full Text] [PDF]

				B. Liu, A. Sutton, and R. Sternglanz A Yeast Polyamine Acetyltransferase J. Biol. Chem., April 29, 2005; 280(17): 16659 - 16664. [Abstract] [Full Text] [PDF]

				L. Nie, W. Feng, R. Diaz, M. A. Gratton, K. J. Doyle, and E. N. Yamoah Functional Consequences of Polyamine Synthesis Inhibition by L-{alpha}-Difluoromethylornithine (DFMO): CELLULAR MECHANISMS FOR DFMO-MEDIATED OTOTOXICITY J. Biol. Chem., April 15, 2005; 280(15): 15097 - 15102. [Abstract] [Full Text] [PDF]

				Y. Guo, J. L. Cleveland, and T. G. O'Brien Haploinsufficiency for Odc Modifies Mouse Skin Tumor Susceptibility Cancer Res., February 15, 2005; 65(4): 1146 - 1149. [Abstract] [Full Text] [PDF]

				W. Choi, E. W. Gerner, L. Ramdas, J. Dupart, J. Carew, L. Proctor, P. Huang, W. Zhang, and S. R. Hamilton Combination of 5-Fluorouracil and N1,N11-Diethylnorspermine Markedly Activates Spermidine/Spermine N1-Acetyltransferase Expression, Depletes Polyamines, and Synergistically Induces Apoptosis in Colon Carcinoma Cells J. Biol. Chem., February 4, 2005; 280(5): 3295 - 3304. [Abstract] [Full Text] [PDF]

				A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3 Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396. [Abstract] [Full Text] [PDF]

				A. L. Subhi, B. Tang, B. R. Balsara, D. A. Altomare, J. R. Testa, H. S. Cooper, J. P. Hoffman, N. J. Meropol, and W. D. Kruger Loss of Methylthioadenosine Phosphorylase and Elevated Ornithine Decarboxylase Is Common in Pancreatic Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7290 - 7296. [Abstract] [Full Text] [PDF]

				C. D. Lao, P. Backoff, L. I. Shotland, D. McCarty, T. Eaton, F. G. Ondrey, J. L. Viner, S. J. Spechler, E. T. Hawk, and D. E. Brenner Irreversible Ototoxicity Associated with Difluoromethylornithine Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1250 - 1252. [Abstract] [Full Text] [PDF]

				M. Kielosto, P. Nummela, R. Katainen, V. Leaner, M. J. Birrer, and E. Holtta Reversible Regulation of the Transformed Phenotype of Ornithine Decarboxylase- and Ras-Overexpressing Cells by Dominant-Negative Mutants of c-Jun Cancer Res., June 1, 2004; 64(11): 3772 - 3779. [Abstract] [Full Text] [PDF]

				L. W. Wattenberg, T. S. Wiedmann, and R. D. Estensen Chemoprevention of Cancer of the Upper Respiratory Tract of the Syrian Golden Hamster by Aerosol Administration of Difluoromethylornithine and 5-Fluorouracil Cancer Res., April 1, 2004; 64(7): 2347 - 2349. [Abstract] [Full Text] [PDF]

				A. Hikosaka, M. Asamoto, N. Hokaiwado, K. Kato, K. Kuzutani, K. Kohri, and T. Shirai Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) Carcinogenesis, March 1, 2004; 25(3): 381 - 387. [Abstract] [Full Text] [PDF]

				Y. Huang, J. C. Keen, E. Hager, R. Smith, A. Hacker, B. Frydman, A. L. Valasinas, V. K. Reddy, L. J. Marton, R. A. Casero Jr., et al. Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells Mol. Cancer Res., February 1, 2004; 2(2): 81 - 88. [Abstract] [Full Text] [PDF]

				A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. K. Carducci, C. D. Riley, J. F. Bender, R. A. Casero Jr., and N. E. Davidson A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5922 - 5928. [Abstract] [Full Text] [PDF]

				D. Soulet and S. Rivest Polyamines play a critical role in the control of the innate immune response in the mouse central nervous system J. Cell Biol., July 21, 2003; 162(2): 257 - 268. [Abstract] [Full Text] [PDF]

				M. E. Martinez, T. G. O'Brien, K. E. Fultz, N. Babbar, H. Yerushalmi, N. Qu, Y. Guo, D. Boorman, J. Einspahr, D. S. Alberts, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene PNAS, June 24, 2003; 100(13): 7859 - 7864. [Abstract] [Full Text] [PDF]

				D. L. Wheeler, K. J. Ness, T. D. Oberley, and A. K. Verma Inhibition of the Development of Metastatic Squamous Cell Carcinoma in Protein Kinase C {epsilon} Transgenic Mice by {alpha}-Difluoromethylornithine Accompanied by Marked Hair Follicle Degeneration and Hair Loss Cancer Res., June 15, 2003; 63(12): 3037 - 3042. [Abstract] [Full Text] [PDF]

				S. M. Fischer, C. J. Conti, J. Viner, C.M. Aldaz, and R. A. Lubet Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis, May 1, 2003; 24(5): 945 - 952. [Abstract] [Full Text] [PDF]

				D. C. Metz and D. S. Alberts Gastrointestinal Cancer Prevention in the United States: The Road Ahead Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 81 - 83. [Full Text] [PDF]

				X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]

				L. L. Siu, E. K. Rowinsky, L. A. Hammond, G. R. Weiss, M. Hidalgo, G. M. Clark, J. Moczygemba, L. Choi, R. Linnartz, N. C. Barbet, et al. A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies Clin. Cancer Res., July 1, 2002; 8(7): 2157 - 2166. [Abstract] [Full Text] [PDF]

				K. R. Lawson, S. Marek, J. A. Linehan, P. M. Woster, R. A. Casero Jr., C. M. Payne, and E. W. Gerner Detoxification of the Polyamine Analogue N1-Ethyl-N11-[(cycloheptyl)methy]-4,8-diazaundecane (CHENSpm) by Polyamine Oxidase Clin. Cancer Res., May 1, 2002; 8(5): 1241 - 1247. [Abstract] [Full Text] [PDF]

				H. I. Quinones, A. F. List, and E. W. Gerner Selective Exclusion by the Polyamine Transporter as a Mechanism for Differential Radioprotection of Amifostine Derivatives Clin. Cancer Res., May 1, 2002; 8(5): 1295 - 1300. [Abstract] [Full Text] [PDF]

				H. Rebel, H. van Steeg, R. B. Beems, R. Schouten, F. R. de Gruijl, and C. Terleth Suppression of UV Carcinogenesis by Difluoromethylornithine in Nucleotide Excision Repair-deficient Xpa Knockout Mice Cancer Res., March 1, 2002; 62(5): 1338 - 1342. [Abstract] [Full Text] [PDF]

				C. A. Hobbs, B. A. Paul, and S. K. Gilmour Deregulation of Polyamine Biosynthesis Alters Intrinsic Histone Acetyltransferase and Deacetylase Activities in Murine Skin and Tumors Cancer Res., January 1, 2002; 62(1): 67 - 74. [Abstract] [Full Text] [PDF]

				N. Ahmad, A. C. Gilliam, S. K. Katiyar, T. G. O'Brien, and H. Mukhtar A Definitive Role of Ornithine Decarboxylase in Photocarcinogenesis Am. J. Pathol., September 1, 2001; 159(3): 885 - 892. [Abstract] [Full Text] [PDF]

				D. J. Feith, L. M. Shantz, and A. E. Pegg Targeted Antizyme Expression in the Skin of Transgenic Mice Reduces Tumor Promoter Induction of Ornithine Decarboxylase and Decreases Sensitivity to Chemical Carcinogenesis Cancer Res., August 1, 2001; 61(16): 6073 - 6081. [Abstract] [Full Text] [PDF]

				K. J. Doyle, C. E. McLaren, J. E. Shanks, C. M. Galus, and F. L. Meyskens Effects of Difluoromethylornithine Chemoprevention on Audiometry Thresholds and Otoacoustic Emissions Arch Otolaryngol Head Neck Surg, May 1, 2001; 127(5): 553 - 558. [Abstract] [Full Text] [PDF]

				L. Y. Y. Fong, V. T. Nguyen, A. E. Pegg, and P. N. Magee {{alpha}}-Difluoromethylornithine Induction of Apoptosis: A Mechanism Which Reverses Pre-established Cell Proliferation and Cancer Initiation in Esophageal Carcinogenesis in Zinc-deficient Rats Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 191 - 199. [Abstract] [Full Text]

				B.-S. Herbert, A. C. Wright, C. M. Passons, W. E. Wright, I. U. Ali, L. Kopelovich, and J. W. Shay Effects of Chemopreventive and Antitelomerase Agents on the Spontaneous Immortalization of Breast Epithelial Cells J Natl Cancer Inst, January 3, 2001; 93(1): 39 - 45. [Abstract] [Full Text] [PDF]

				A. R. Simoneau, E. W. Gerner, M. Phung, C. E. McLaren, and F. L. Meyskens Jr. {{alpha}}-Difluoromethylornithine and Polyamine Levels in the Human Prostate: Results of a Phase IIa Trial J Natl Cancer Inst, January 3, 2001; 93(1): 57 - 59. [Full Text] [PDF]

				S. M. Fischer, M. Lee, and R. A. Lubet Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice Carcinogenesis, January 1, 2001; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]

				A. Paasinen-Sohns, M. Kielosto, E. Kaariainen, T. Eloranta, A. Laine, O. A. Janne, M. J. Birrer, and E. Holtta c-Jun Activation-dependent Tumorigenic Transformation Induced Paradoxically by Overexpression or Block of S-Adenosylmethionine Decarboxylase J. Cell Biol., November 13, 2000; 151(4): 801 - 810. [Abstract] [Full Text] [PDF]

				Y. Guo, R. B. Harris, D. Rosson, D. Boorman, and T. G. O’Brien Functional Analysis of Human Ornithine Decarboxylase Alleles Cancer Res., November 1, 2000; 60(22): 6314 - 6317. [Abstract] [Full Text]

				L. Lan, C. Trempus, and S. K. Gilmour Inhibition of Ornithine Decarboxylase (ODC) Decreases Tumor Vascularization and Reverses Spontaneous Tumors in ODC/Ras Transgenic Mice Cancer Res., October 1, 2000; 60(20): 5696 - 5703. [Abstract] [Full Text]

				S. Gupta, N. Ahmad, S. R. Marengo, G. T. MacLennan, N. M. Greenberg, and H. Mukhtar Chemoprevention of Prostate Carcinogenesis by {{alpha}}-Difluoromethylornithine in TRAMP Mice Cancer Res., September 1, 2000; 60(18): 5125 - 5133. [Abstract] [Full Text]

				K. Ravanko, K. Järvinen, A. Paasinen-Sohns, and E. Hölttä Loss of p27Kip1 from Cyclin E/Cyclin-dependent Kinase (CDK) 2 but not from Cyclin D1/CDK4 Complexes in Cells Transformed by Polyamine Biosynthetic Enzymes Cancer Res., September 1, 2000; 60(18): 5244 - 5253. [Abstract] [Full Text]

				M. L. McWilliams, G.-D. Chen, and L. D. Fechter Characterization of the Ototoxicity of Difluoromethylornithine and Its Enantiomers Toxicol. Sci., July 1, 2000; 56(1): 124 - 132. [Abstract] [Full Text] [PDF]

				W. W. and C. M. Higuchi Dietary Soy Protein Is Associated with Reduced Intestinal Mucosal Polyamine Concentration in Male Wistar Rats J. Nutr., July 1, 2000; 130(7): 1815 - 1820. [Abstract] [Full Text]

				P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]

				J. A. O'Shaughnessy, L. M. Demers, S. E. Jones, J. Arseneau, P. Khandelwal, T. George, R. Gersh, D. Mauger, and A. Manni {{alpha}}-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients Clin. Cancer Res., November 1, 1999; 5(11): 3438 - 3444. [Abstract] [Full Text] [PDF]

				M. Belting, L. Borsig, M. M. Fuster, J. R. Brown, L. Persson, L.-A. Fransson, and J. D. Esko Tumor attenuation by combined heparan sulfate and polyamine depletion PNAS, January 8, 2002; 99(1): 371 - 376. [Abstract] [Full Text] [PDF]